Get the Stockscreener App
1.44
5.88%
0.08
Black Diamond Therapeutics Inc stock is traded at $1.44, with a volume of 661.99K.
It is up +5.88% in the last 24 hours and down -15.79% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$1.36
Open:
$1.35
24h Volume:
661.99K
Relative Volume:
0.22
Market Cap:
$79.33M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-0.766
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
+1.41%
1M Performance:
-15.79%
6M Performance:
-55.28%
1Y Performance:
-74.74%
1-Day Range:
$1.31
$1.45
1-Week Range:
$1.31
$1.49
52-Week Range:
$1.195
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
1.44 | 79.33M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Head-To-Head Contrast: Avalon GloboCare (NASDAQ:ALBT) and Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Acquired by Wellington Management Group LLP - Defense World
Raymond James Financial Inc. Purchases New Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Sei Investments Co. Purchases Shares of 22,802 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond stock hits 52-week low at $1.42 amid challenges - Investing.com India
Black Diamond stock hits 52-week low at $1.42 amid challenges By Investing.com - Investing.com South Africa
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Stock Holdings Raised by Intech Investment Management LLC - The AM Reporter
Bank of New York Mellon Corp Purchases 65,341 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics’ Global Licensing Deal with Servier - Global Legal Chronicle
BDTX stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
What is Wedbush’s Estimate for BDTX Q1 Earnings? - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 37,472 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BB Biotech AG Reduces Stake in Black Diamond Therapeutics Inc - GuruFocus
Black Diamond Therapeutic Stock Price, Quotes and Forecasts | NASDAQ:BDTX - Benzinga
Stock Traders Buy High Volume of Call Options on Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Growth Stocks To Add to Your Watchlist – March 19th - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Earns “Outperform” Rating from Wedbush - Defense World
HC Wainwright Has Bearish Forecast for BDTX Q1 Earnings - Defense World
Black Diamond Therapeutics sees $11.99m stock sale by BB Biotech AG - Investing.com
Growth Stocks To Add to Your WatchlistMarch 19th - MarketBeat
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Yea - Asianet Newsable
Black Diamond Therapeutics Surge: Savvy Move or Bubble? - timothysykes.com
Black Diamond Gets The Gift Of Time In License Pact With Servier - insights.citeline.com
Servier and Black Diamond enter oncology licensing deal By Investing.com - Investing.com South Africa
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, a Targeted Oncology Therapy - Marketscreener.com
Sector Update: Health Care -March 19, 2025 at 03:43 pm EDT - Marketscreener.com
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High - NewsBreak: Local News & Alerts
This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement - The Globe and Mail
Black Diamond Therapeutics surges on licensing deal - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Benzinga
Black Diamond Therapeutics (BDTX) Stock Jumps After Entering Licensing Deal - Stocks Telegraph
Black Diamond stock surges on licensing deal (BDTX:NASDAQ) - Seeking Alpha
Servier and Black Diamond collaborate on BDTX-4933 - The Pharma Letter
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors - Marketscreener.com
Servier and Black Diamond enter oncology licensing deal - Investing.com India
Black Diamond rises on licensing deal for tumor treatment - TradingView
Black Diamond stock soars on licensing deal By Investing.com - Investing.com Australia
Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy - Marketscreener.com
Servier and Black Diamond Therapeutics Announce Global - GlobeNewswire
HC Wainwright Issues Positive Forecast for Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price - Defense World
Black Diamond Therapeutics Reports 2024 Financial Results - MSN
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):